Pulmonary artery hypertension patients and the coronavirus disease of 2019 (COVID-19): are they protected from severe disease?

https://doi.org/10.19106/JMedSciSI005203202008

Anggoro Budi Hartopo(1*), Dyah Wulan Anggrahini(2), Bambang Budi Siswanto(3), Lucia Kris Dinarti(4)

(1) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Working Group on Pulmonary Hypertension, Indonesian Heart Association
(2) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Working Group on Pulmonary Hypertension, Indonesian Heart Association
(3) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia/National Cardiovascular Center Harapan Kita, Jakarta, Working Group on Pulmonary Hypertension, Indonesian Heart Association
(4) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Working Group on Pulmonary Hypertension, Indonesian Heart Association
(*) Corresponding Author

Abstract


The coronavirus disease of 2019 (COVID-19) is a current pandemic of viral infection which mainly involves respiratory system and may progress into severe multiple organ dysfunction and mortality. Pulmonary artery hypertension (PAH) is a disease marked by increased mean pulmonary artery pressure and pulmonary vascular resistance due to pulmonary panvascular remodeling. Although rare, the prevalence of PAH is currently escalating in Indonesia due to increased diagnostic capacity and referral, treatment availability and improved survival. Despite chronic cardiac and pulmonary diseases are at increased risk to develop severe COVID-19, patients with PAH are considered to be not in higher risk to develop severe COVID-19. However, whether this population is protected from severe COVID-19 is unclear. There are protective and offensive factors need to be considered in PAH patients in respect to COVID-19.


Keywords


COVID-19; pulmonary artery hypertension; severity; risk factor;

Full Text:

PDF


References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia inChina, 2019. N Engl J Med 2020; 382:727-33. https://doi.org/10.1056/NEJMoa2001017
  2. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact ofcardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109:531-8. https://doi.org/10.1007/s00392-020-01626-9
  3. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020; 12:6049-57. https://doi.org/10.18632/aging.103000
  4. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; 75(18):2352-71. https://doi.org/10.1016/j.jacc.2020.03.031
  5. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med 2020. https://doi.org/10.1164/rccm.202003-0543OC
  6. Ryan JJ, Melendres-Groves L, Zamanian RT, Oudiz RJ, Chakinala M, Rosenzweig EB, et al. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ 2020; 10(2). https://doi.org/10.1177/2045894020920153
  7. Prins KW, Thenappan T. WHO group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin 2016; 34:363-74. https://doi.org/10.1016/j.ccl.2016.04.001
  8. Horn E, Chakinala MM, OudizR, Joseloff E, Rosenzweig EB. Could pulmonary arterial hypertension (PAH) patients be at a lower risk from severe COVID-19? Pulm Circ 2020. https://doi.org/10.1177/2045894020922799
  9. Zhou H, Zhang G, Deng X, Jin B, Qiu Q, Yan M, et al. Understanding the current status of patients with pulmonary hypertension during COVID-19 outbreak: a small scale national survey from China. Pulm Circ 2020. https://doi.org/10.1177/2045894020924566
  10. Farha S. COVID-19 and pulmonary hypertension. Cleve Clin J Med 2020; ccc021. https://doi.org/10.3949/ccjm.87a.ccc021
  11. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD, et al. The congenital heart disease in adult and pulmonary hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord 2020; 20:163. https://doi.org/10.1186/s12872-020-01434-z
  12. Austin ED, Rock MT, Mosse CA, Vnencak-Jones CL, Yoder SM, Robbins IM, et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2010; 104:454-62. https://doi.org/10.1016/j.rmed.2009.10.004
  13. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis 2020; 221:1762‐9. https://doi.org/10.1093/infdis/jiaa150
  14. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179:1048-54. https://doi.org/10.1164/rccm.200811-1678OC
  15. Dalan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res 2020; 52:257‐63. https://doi.org/10.1055/a-1155-0501
  16. Lilyasari O, Subekti Y, Atika N, Dinarti LK, Putri S, Opitasari C, et al. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. BMC Health Serv Res 2019; 19:573. https://doi.org/10.1186/s12913-019-4422-5
  17. Fernandes T, Papamatheakis D, Poch D, Kim N H. EXPRESS: Letter to the Editor Regarding “Could pulmonary arterial hypertension (PAH) patients be at lower risk from severe COVID-19?” Pulmonary Circulation 2020. https://doi.org/10.1177/2045894020925761
  18. Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raudan F, Carvajal-Rodriguez F, Dutschmann M, et al. Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude? Respir Physiol Neurobiol 2020; 103443. https://doi.org/10.1016/j.resp.2020.103443
  19. Morinet F, Parent M, Bergeron C, Pillet S, Capron C. Oxygen and viruses: a breathing story. J Gen Virol 2015; 96:1979-82. https://doi.org/10.1099/vir.0.000172
  20. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol 2020; 309:70-7. https://doi.org/10.1016/j.ijcard.2020.03.063
  21. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014; 115:165-75. https://doi.org/10.1161/CIRCRESAHA.113.301141
  22. Sandoval J, Del Valle-Mondragón L, Masso F, Zayas N, Pulido T, Teijeiro R, et al. Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertension. Eur Respir J 2020. pii: 1902416. https://doi.org/10.1183/13993003.02416-2019
  23. Badagliacca R, Sciomer S, Petrosillo N. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: friend or foe? J Heart Lung Transplant 2020; S1053-2498(20)31513-8. https://doi.org/10.1016/j.healun.2020.04.007



DOI: https://doi.org/10.19106/JMedSciSI005203202008

Article Metrics

Abstract views : 3052 | views : 2824


Bookmark and Share


Copyright (c) 2020 Anggoro Budi Hartopo, Dyah Wulan Anggrahini, Bambang Budi Siswanto, Lucia Kris Dinarti

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.